高血压诊治热点研究进展  

Research Progress of Hotspots in Diagnosis and Treatment of Hypertension

作　　者：李金根 马立永 张立晶[1] LI Jingen;MA Liyong;ZHANG Lijing(First Department of Cardiology,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China)

机构地区：[1]北京中医药大学东直门医院心血管一科,北京100700

出　　处：《医学综述》2020年第23期4666-4671,共6页Medical Recapitulate

基　　金：国家重点研发计划(2017YFC1700400);中央高校基本科研业务费项目(2020-JYB-ZDGG-116)。

摘　　要：高血压是一种高患病率、高致残率的慢性疾病,是心血管疾病的重要独立危险因素。近年来关于高血压的划分界限、降压治疗的目标值是否越低越好及最佳舒张压水平、是否仍应将β受体阻滞剂作为一线降压药物等问题仍存在争议。现有证据仍支持将β受体阻滞剂作为一线降压药物,将高血压定义为≥130/80 mmHg及将所有风险人群的降压目标值设定为<130/80 mmHg可能过于严格,对于老年高血压降压目标值的界定及舒张压的最佳水平证据尚不充分。因此,针对最佳舒张压水平问题应开展前瞻性随机对照研究以进一步研究确定。Hypertension,a chronic disease with high prevalence and a major cause of disability,is an important independent risk factor for cardiovascular disease.Recently,issues regarding definition of hypertension,blood pressure goals in general and elderly patients,optimal diastolic blood pressure and whetherβblockers can still be used as first-line antihypertensive agents are controversial.The existing evidence still supports the use ofβblockers as first-line antihypertensive drugs.Defining hypertension as≥130/80 mmHg and setting the blood pressure target as<130/80 mmHg may be too aggressive;evidence for blood pressure target in the elderly and optimal diastolic blood pressure is inadequate.Therefore,further prospective randomized studies are needed to provide evidence for these issues,especially the issue regarding optimal diastolic blood pressure.

关 键 词：高血压 降压目标值 舒张压 Β受体阻滞剂 

分 类 号：R544[医药卫生—心血管疾病]